“Global Antibacterial Drugs market set to grow to $48bn by 2024” says new Visiongain report

26 April 2019
Pharma

Visiongain has launched a new pharma report Global Antibacterial Drugs Market Report : Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others.

The demand for antibacterial drugs will continue as bacterial infections are among the most common diseases worldwide. However, strong efforts to restrict antibiotic prescribing in developed and emerging markets will not only reduce bacterial resistance but will also restrain growth. The development of novel therapies, on the other hand, will be driven by increased government investment and funding from other public bodies.

The lead analyst of the report commented "As with other sectors of the pharmaceutical industry, future antibacterial drug development will be driven by innovation from small bio pharmaceutical companies, Visiongain believes.

Many of the most novel products in the development pipeline have come from small companies targeting new treatment pathways or mechanisms of action. Increased demand and funding from governments for new antibacterial drugs will benefit these small companies over the coming 10 years."

Leading companies featured in the report include Adenium Biotech ApS, Allecra Therapeutics GmbH, AstraZeneca, Bayer, BioVersys AG, Eli Lilly. GlaxoSmithKline (GSK), Merck & Co., Novartis, Pfizer and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever